The final sum breezed by the target $2.5 billion.

ASG has been expanding its real estate offerings.

Aeon will screen short-term loans for ESG considerations.

It's easy to shake your head at a multiverse "property" but you have to step back and see what the actual strategy is.

For many, the choice is to buy a cap anyway to finance or sell off the property.

Some companies in biotech and pharma are likely to feel a strong pinch, and that could get passed on to real estate spending.

The only exception by asset class was hotels.

The lanes to continued success seem to be clear, but how long can the supporting trends last?